Despite his premature death, Carl Judie lives on in Dhar Mann videos – and in the hearts of fans who cherished his work. Beloved Actor, Who Was Just Getting Started, Would Have Turned 65 Today ...

Content creator Dhar Mann and Bell Media President Sean Cohan will keynote the 2026 editions, which will take place at the InterContinental Miami from February 2-6.

Creator and entrepreneur Dhar Mann is making after-school specials for the digital age. His popular YouTube channel, which boasts 25.5 million subscribers, features high-production scripted shorts ...

Office With a View: The creator-enterprenuer scales his mission-driven content from short-form to an app, production studio and live tour.

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to ...

“During the quarter, we initiated a new position in Eli Lilly and Company (NYSE:LLY), a global pharmaceutical company currently best known for GLP-1 medications for diabetes and obesity.

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of ...

NEED TO KNOW Shahs of Sunset alum Lilly Ghalichi filed for divorce from husband Dara Mir after eight years of marriage This is the fourth time the former couple have filed for divorce over the ...

The latest Lilly Pulitzer Reserve Collection offers heirloom-quality dresses, tops, and matching sets. Shop the limited-edition drop here.

Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.

In April 2025, Eli Lilly and Company (Lilly) filed lawsuits in the U.S. District Court for the Northern District of California against telehealth companies, alleging the companies sell illegal ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players ...